Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

X
Drug Profile

Relatlimab - Bristol-Myers Squibb/Ono Pharmaceuticals

Alternative Names: Anti-LAG-3; Anti-LAG-3 monoclonal antibody - Bristol-Myers Squibb; Anti-LAG-3-Bristol-Myers-Squibb; Anti-lymphocyte activation gene 3 monoclonal antibody; BMS 986016; ONO-4482

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Herlev Hospital; Multiple Myeloma Research Consortium; National Institute of Neurological Disorders and Stroke; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital of Essen; University of Miami; University of Pittsburgh
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Uveal melanoma
  • Phase I/II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Fallopian tube cancer; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Oesophageal cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Glioblastoma

Most Recent Events

  • 06 May 2024 National Cancer Institute (NCI) withdraws a phase II trial in Solid tumours (Combination therapy, Late stage disease, Second line therapy or greater) (IV) (NCT06400264)
  • 18 Jan 2024 Bristol-Myers Squibb completes the phase I RELATIVITY-111 trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (IV) (NCT05498480)
  • 03 Oct 2023 National Cancer Institute (NCI) and Bristol Myers Squibb completes a phase-I development in Glioblastoma (Monotherapy, Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV, Infusion) (NCT02658981)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top